Det var derfor CHMP’ s opfattelse, at fordelene opvejer de identificerede risici som for Zyprexa og Zyprexa Velotab.
Therefore, the CHMP’ s view was that, as for Zyprexa and Zyprexa Velotab, the benefit outweighs the identified risk.